share_log

Cellectar Biosciences Says Cash and Cash Equivalents Of $9.6M And Funds Generated By Warrants Exercised In 2023 Of $22.9M Is Expected To Provide Cash Runway Into Q4 2024

Cellectar Biosciences Says Cash and Cash Equivalents Of $9.6M And Funds Generated By Warrants Exercised In 2023 Of $22.9M Is Expected To Provide Cash Runway Into Q4 2024

Cellectar Biosciences表示,960萬美元的現金和現金等價物以及2023年行使的2,290萬美元的認股權證產生的資金預計將爲2024年第四季度提供現金流道
Benzinga ·  03/27 18:52

Cellectar Biosciences Says Cash and Cash Equivalents Of $9.6M And Funds Generated By Warrants Exercised In 2023 Of $22.9M Is Expected To Provide Cash Runway Into Q4 2024

Cellectar Biosciences表示,960萬美元的現金和現金等價物以及2023年行使的2,290萬美元的認股權證產生的資金預計將爲2024年第四季度提供現金流道

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論